Efficacy of Eicosapentaenoic acid Supplementation on the Serum Profile of Lp (a) in the Patients with Type 2 Diabetes Mellitus

摘要

Background: The serum levels of Lp (a) is considered as a risk factor and a predictor of atherosclerotic vascular disease. The patients with type 2 diabetes mellitus have an increased in the serum levels of Lp (a), and endothelial dysfunction. EPA has the antioxidant, antiinflammatory, antithrombogenic, and antiarteriosclerotic properties. Therefore, we investigated the efficacy of Eicosapentaenoic acid supplementation on the serum profile of Lp (a) in the diabetic patients. Methods: This study was designed as a randomized, double-blind, and placebo-controlled clinical trial. Thirty six patients with type 2 diabetes were given written; informed consent, randomly were classified into 2 groups. They were supplemented with 2 g/day of the capsules of EPA or placebo. At the start and the end of the intervention, blood sample for measurement of the serum levels of Lp (a), and lipids, as well as FBS and HbA1c were given. Results: There were no significant differences between the two groups regarding any demographic, clinical or biochemical data, total energy intake, and macronutrient intake at the baseline, and during the intervention, except for a significant increase of protein intake and the levels of HbA1c in the placebo group, and a significant increase of HDL-c, and a significant decrease in the serum levels Lp (a), as well as a slight reduce of TC, LDL-c, TG and FBS in the supplement group. Conclusions: EPA is atheroprotective via decrease in the serum levels of Lp (a), as well as change in the serum levels of lipids, and FBS.